Literature DB >> 8369807

Reciprocal changes in complement activity and immune-complex levels during plasma infusion in a C2-deficient SLE patient.

K Erlendsson1, K Traustadóttir, J Freysdóttir, K Steinsson, I Jónsdóttir, H Valdimarsson.   

Abstract

Although systemic lupus erythematosus (SLE) is abnormally common in individuals with complement deficiency, conclusive evidence has been lacking for a direct causal relationship between disease manifestations and a missing complement component. A patient with C2 deficiency and SLE has been treated with 56 courses of fresh frozen plasma (FFP) infusions over a period of 8 years. Each infusion, involving a total of 12 units of FFP administered in equal doses over 4 consecutive days, has consistently resulted in a transient restoration of the classical pathway of complement, and a full clinical remission lasting 6-8 weeks. This report is concerned with changes in the levels of immune complexes, C2 and C3d during an infusion cycle. Four progressively rising peaks in C2 and C3d were observed during the 4 days of the plasma infusion, and these peaks coincided with four reciprocally descending troughs in the levels of immune complexes. Identical fluctuations have been consistent in all the plasma-infusion cycles that have so far been monitored, and their consistent association with clinical remissions indicates a causal relationship between the C2 restoration and clinical remissions in this C2-deficient SLE patient.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8369807     DOI: 10.1177/096120339300200306

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  6 in total

1.  Mannan-binding lectin may facilitate the clearance of circulating immune complexes--implications from a study on C2-deficient individuals.

Authors:  S Saevarsdottir; K Steinsson; B R Ludviksson; G Grondal; H Valdimarsson
Journal:  Clin Exp Immunol       Date:  2007-03-05       Impact factor: 4.330

2.  Comparative and correlative assessments of cytokine, complement and antibody patterns in paediatric type 1 diabetes.

Authors:  M Abdel-Latif; A A Abdel-Moneim; M H El-Hefnawy; R G Khalil
Journal:  Clin Exp Immunol       Date:  2017-07-13       Impact factor: 4.330

Review 3.  Complement deficiencies in systemic lupus erythematosus.

Authors:  Angela R Bryan; Eveline Y Wu
Journal:  Curr Allergy Asthma Rep       Date:  2014-07       Impact factor: 4.806

4.  C1q deficiency: identification of a novel missense mutation and treatment with fresh frozen plasma.

Authors:  Rezan Topaloglu; Ekim Z Taskiran; Cagman Tan; Baran Erman; Fatih Ozaltin; Ozden Sanal
Journal:  Clin Rheumatol       Date:  2012-05-11       Impact factor: 2.980

5.  Recombinant human complement component C2 produced in a human cell line restores the classical complement pathway activity in-vitro: an alternative treatment for C2 deficiency diseases.

Authors:  Paolo G V Martini; Lynette C Cook; Scott Alderucci; Angela W Norton; Dianna M Lundberg; Susan M Fish; Knut Langsetmo; Göran Jönsson; Christian Lood; Birgitta Gullstrand; Kate J Zaleski; Nancy Savioli; Jason Lottherand; Charles Bedard; John Gill; Michael F Concino; Michael W Heartlein; Lennart Truedsson; Jan L Powell; Arthur O Tzianabos
Journal:  BMC Immunol       Date:  2010-08-20       Impact factor: 3.615

Review 6.  Cell-Free DNA as a Biomarker in Autoimmune Rheumatic Diseases.

Authors:  Bhargavi Duvvuri; Christian Lood
Journal:  Front Immunol       Date:  2019-03-19       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.